Exhibit 10.4
 
PREFERRED STOCK DRAWDOWN AGREEMENT

 
THIS PREFERRED STOCK DRAWDOWN AGREEMENT (this “Agreement”) is made as of
November 7, 2011 by and between BioNeutral Group, Inc., a Nevada corporation
(the “Company”), and Vinfluence Pty Ltd ACN 147 137 899 (“Purchaser”).
 
RECITALS
 
WHEREAS, the Company desires to sell to Purchaser and Purchaser desires to
purchase from the Company the number of shares of the Company’s Series E
Convertible Preferred Stock (“Preferred Stock”) set forth herein at a price of
$10.00 per share, subject to the terms and conditions of this Agreement and the
other documents or instruments contemplated hereby.
 
 NOW, THEREFORE, the parties hereto hereby agree as follows:
 
AGREEMENT
 
Section 1.             Sale and Issuance of Preferred Stock.
 
(a) Subject to the terms and conditions of this Agreement, the Company has
authorized the sale and issuance (the "Issuance") to Purchaser of an aggregate
of up to 140,000 shares of the Preferred Stock at $10.00 per share for an
aggregate commitment amount of up to $1,400,000 (the “Aggregate Commitment”)
which the Purchaser has agreed to provide to the Company on a monthly basis
commencing on April 1, 2012 and ending on October 1, 2012 (the “Commitment
Period”) in order to purchase Preferred Stock pursuant to the terms and
conditions of this Agreement. The Purchaser shall purchase an aggregate of up to
140,000 shares of Preferred Stock in monthly increments of up to $200,000 (the
“Maximum Advance Amount”), upon receipt of a Drawdown Notice from the
Company.  Drawdown Notice shall mean a written notice in the form of Exhibit A
attached hereto to the Purchaser setting forth the amount of the advance.
 
(b) The rights and preferences of the Preferred Stock shall be set forth in a
Certificate of Designations and Preferences to be filed with the Secretary of
State of the State of Nevada in form and substance as set forth on Exhibit B
hereto.
 
Section 2.              Mechanics/Closings.
 
2.1          Drawdown Notice. On a monthly basis during the Commitment Period,
the Company may request the Purchaser to purchase shares of Preferred Stock by
delivering a Drawdown Notice to the Investor, subject to the conditions set
forth herein; provided, however, the amount for each Advance as designated by
the Company in the applicable Drawdown Notice shall not be more than the Maximum
Advance Amount and the aggregate amount of the Advances pursuant to this
Agreement shall not exceed the Aggregate Commitment.  The Company shall have
discretion as to whether it issues a Drawdown Notice to sell shares of Preferred
Stock, and, except for conditions outside the Purchaser’s control, the Purchaser
shall be obligated to purchase from the Company, shares of the Preferred Stock
as requested in the Drawdown Notice.
 
 
1

--------------------------------------------------------------------------------

 
 
2.2          Date of Delivery of Drawdown Notice. A Drawdown Notice shall be
deemed delivered on: (i) the Trading Day it is received by email to
Wayne@Noblemenventures.com if such notice is received prior to 5:00 pm Eastern
Time; or (ii) the immediately succeeding Trading Day if a Drawdown Notice is
received by facsimile or otherwise after 5:00 pm Eastern Time on a Trading Day
or at any time on a day which is not a Trading Day.  No Drawdown Notice may be
deemed delivered on a day that is not a Trading Day.
 
2.3         Each Closing shall take place within three (3) business days of the
Purchaser’s receipt of a Drawdown Notice issued by the Company, provided the
conditions set forth in Section 5.2 below have been satisfied.
 
2.4         At each Closing, the Company shall issue and deliver to Gersten
Savage, LLP, as escrow agent (“Escrow Agent”), a stock certificate representing
the Preferred Stock, against receipt by Escrow Agent of a wire transfer in an
amount equal to the Purchase Price.  Upon receipt of the Purchase Price and the
Preferred Stock certificate for each Closing, and in accordance with the Escrow
Agreement entered into by each of Purchaser and Company, Escrow Agent shall
release the Purchase Price to the Company and the Preferred Stock certificate to
the Buyer.
 
Section 3.             Representations and Warranties of the Company.
 
The Company hereby represents and warrants to Purchaser as follows:
 
3.1           Capitalization of the Company. Immediately prior to the date
hereof, the authorized capital stock of the Company shall consist of a total of
200,000,000 shares of Common Stock, $0.00001 par value per share (the “Common
Stock”) of which 79,389,092 are issued and outstanding, (this number includes
the conversion of the 83,762 shares of preferred stock of BioNeutral
Laboratories Corporation USA (“Bio USA”)) and 5,000,000 shares of Preferred
Stock, $0.001 par value, of which 800,000 are designated as Series A, 213,500
are designated as Series B, 100,000 are designated as Series C, 231,100 are
designated as Series D and 140,000 are designated as Series E.  There are 83,762
shares of Series A preferred stock outstanding of BioN USA which can be
converted into common stock and no shares of Series B, Series C, Series D or
Series E preferred stock outstanding.  Other than as set forth in the Company’s
filings with the Securities and Exchange Commission (“Filings”), there are no
commitments to issue, and there are no outstanding warrants, options,
convertible securities or debt, preferred stock, or any other securities as of
the date of Closing, except as set forth herein.  In addition, other than as set
forth in the Company’s Filings, there are no conversion or exchange privileges,
preemptive rights, or other rights or agreements to purchase or otherwise
acquire or issue any securities of the Company, and there is no agreement or
understanding between any persons and/or entities, which affects or relates to
the voting or giving of written consents with respect to any security of the
Company or any instrument or security exercisable or exchangeable for, or
convertible into any security of the Company, except that the Company has an
obligation to issue certain shares of common stock as set forth in Schedule A
hereto.
 
 
2

--------------------------------------------------------------------------------

 
 
3.2          Organization.
 
The Company is duly organized, validly existing and in good standing under the
laws of the State of Nevada and is qualified to conduct its business as a
foreign corporation in each jurisdiction where the failure to be so qualified
would have a material adverse effect on the Company.
 
3.3          Authorization of Agreement, Etc.
 
The execution, delivery and performance by the Company of this Agreement and
each other document or instrument contemplated hereby or thereby (collectively,
the "Financing Documents") have been duly authorized by all requisite corporate
action by the Company; and this Agreement and each other Financing Document have
been duly executed and delivered by the Company.  Each of the Financing
Documents, when executed and delivered by the Company, constitutes the valid and
binding obligation of the Company, enforceable against the Company in accordance
with its terms, subject to applicable bankruptcy, insolvency, reorganization,
fraudulent conveyance, moratorium or other similar laws affecting creditors'
rights and remedies generally, and subject as to enforceability to general
principles of equity (regardless of whether enforcement is sought in a
proceeding at law or in equity).
 
3.4          Subsidiaries.

The Company does not own, directly or indirectly, any capital stock or other
equity securities of any other corporation, partnership, limited liability
company, association or other business entity other than as set forth in the
Filings. The Company is not a participant in any joint venture, partnership or
similar arrangement.  The Company owns 89.6% of Bioneutral Laboratories
Corporation USA.

3.5          Financial Statements.

The Company’s financial statements (“Financial Statements”) contained in its
Filings have been prepared in accordance with U.S. GAAP applied on a consistent
basis throughout the periods indicated and with each other, except that the
unaudited Financial Statements do not contain all footnotes required by U.S.
GAAP.  The Financial Statements fairly present the financial condition and
operating results of the Company as of the dates, and for the periods, indicated
therein, subject to normal year-end audit adjustments.  Except as set forth in
the Financial Statements, the Company has no material liabilities (contingent or
otherwise).  Except as disclosed in the Financial Statements, the Company is not
a guarantor or indemnitor of any indebtedness of any other person, firm or
corporation.  The Company maintains and will continue to maintain a standard
system of accounting established and administered in accordance with U.S. GAAP
until Closing.

3.6          No Conflicts.

Neither the Company, nor any subsidiary, is in violation of, in conflict with,
in breach of or in default under any term or provision of, and no right of any
party to accelerate, terminate, modify or cancel has come into existence under,
(i) its Certificate of Incorporation or By-laws (each as may have been amended,
supplemented or restated), (ii) any provision of any judgment, writ, injunction,
decree or order to which the any of them is a party; or (iii) any law, statute,
rule or regulation applicable to any of them.
 
 
3

--------------------------------------------------------------------------------

 
 
3.7          Litigation.

There is no action, suit, proceeding or investigation pending or currently
threatened against the Company or any subsidiary that may affect the validity of
this Agreement or the right of the Company to enter into this Agreement or to
consummate the transactions contemplated hereby.  There is no action, suit,
proceeding or investigation pending or currently threatened against the Company
or its subsidiaries, before any court or by or before any governmental body or
any arbitration board or tribunal, nor is there any judgment, decree, injunction
or order of any court, governmental department, commission, agency,
instrumentality or arbitrator against the Company or any of its subsidiaries
other than these described in the Filings.  The Company and its subsidiaries are
not a party or subject to the provisions of any order, writ, injunction,
judgment or decree of any court or government agency or instrumentality.  There
is no action, suit, proceeding or investigation by the Company or any subsidiary
currently pending or which the Company intends to initiate.

3.8          ‘34 Act Reports.

None of the Company’s Filings contains any untrue statement of a material fact
or omits to state a material fact necessary to make the statements therein not
misleading, in light of the circumstances in which they were made.  For the
period between the filing of the Company’s Form 10-Q for the period ended July
31, 2011 and the date of this Agreement, the Company has made all required
filings and disclosures on Form 8-K pursuant to the rules and regulations
promulgated thereunder.

Section 4.              Representations and Warranties of Purchaser.
 
Purchaser hereby represents and warrants to the Company that each of the
following representations and warranties will be true as of the date hereof:
 
4.1          Authorization of the Documents.
 
Purchaser has all requisite power and authority (corporate or otherwise) to
execute, deliver and perform the Financing Documents and the transactions
contemplated thereby, and the execution, delivery and performance by Purchaser
of the Financing Documents have been duly authorized by all requisite action by
Purchaser and each such Financing Document, when executed and delivered by
Purchaser, constitutes a valid and binding obligation of Purchaser, enforceable
against Purchaser in accordance with its terms, subject to applicable
bankruptcy, insolvency, reorganization, fraudulent conveyance, moratorium or
other similar laws affecting creditors' rights and remedies generally, and
subject, as to enforceability, to general principles of equity (regardless of
whether enforcement is sought in a proceeding at law or in equity).
 
 
4

--------------------------------------------------------------------------------

 
 
4.2          Investment Representations.
 
All of the representations, warranties and information of Purchaser provided in
the Subscription Application dated ___________ are incorporated herein and made
a part hereof by this reference and shall be true at the Closing with the same
effect as though made at the Closing.
 
4.3          Review of Public Filings.
 
Purchaser has had the ability to review all of the Company’s filings and to ask
the Company any questions in connection with its review thereof.
 
Section 5.             Conditions for Advance and Conditions to Closing.
 
5.1          Conditions Precedent to the Obligations of the Company.  The
obligation hereunder of the Company to issue and sell the shares of Common Stock
to the Purchaser incident to each Closing is subject to the satisfaction, or
waiver by the Company, at or before each such Closing, of each of the conditions
set forth below.
 
(a) Accuracy of the Purchaser’s Representations and Warranties.  The
representations and warranties of the Purchaser shall be true and correct in all
material respects.
 
(b) Performance by the Purchaser.  The Purchaser shall have performed, satisfied
and complied in all respects with all covenants, agreements and conditions
required by this Agreement to be performed, satisfied or complied with my the
Purchaser at or prior to such Closing.
 
5.2          Conditions Precedent to the Right of the Company to Deliver a
Drawdown Notice.  The right of the Company to deliver a Drawdown Notice is
subject to the fulfillment by the Company, on such Drawdown Notice (a “Condition
Satisfaction Date”), of each of the following conditions:
 
(a)  Fundamental Changes.  There shall not exist any material adverse changes to
the market or the business of the Company, as determined by the Purchaser in its
sole discretion.
 
(b)  Performance by the Company.  The Company shall have performed, satisfied
and complied in all materials respects with all covenants, agreements and
conditions required by this Agreement to be performed satisfied or complied with
by the Company at or prior to each Closing and the Company shall not be in
breach or default of any other agreement between Company and Purchaser.
 
(c)   No Injunction.  No statute, rule, regulation, executive order, decree,
ruling or injunction shall have been enacted, entered, promulgated or endorsed
by any court or governmental authority or competent jurisdiction that prohibits
or directly and adversely affects any of the transactions contemplated by this
Agreement, and no proceeding shall have been commenced that may have the effect
of prohibiting or adversely affecting any of the transactions contemplated by
this Agreement.
 
 
5

--------------------------------------------------------------------------------

 
 
(d)  No Suspension of Trading in or Delisting of Common Stock. The trading of
the Common Stock is not suspended by the SEC or the Principal Market (if the
Common Stock is traded on a Principal Market).  The issuance of shares of Common
Stock with respect to the applicable Closing, if any, shall not violate the
shareholder approval requirements of the Principal Market (if the Common Stock
is traded on a Principal Market).  The Company shall not have received any
notice threatening the continued listing or quotation of the Common Stock on the
Principal Market (if the Common Stock is traded on a Principal Market).  For
purposes hereof a “Principal Market” shall mean any of the following: OTC
Bulletin Board, OTC Markets, Nasdaq Stock Market, NYSE Amex, or NYSE.
 
(e)          Maximum Advance Amount. The amount of an Advance requested by the
Company shall not exceed the Maximum Advance Amount.
 
(f)           34 Act Filings. The Company shall have timely made all filings
(“SEC Filings”) required to be made by it pursuant to applicable securities laws
(including without limitation, all filings required under the Securities
Exchange Act of 1934, which include Forms 10-Q, 10-K, 8-K, etc.) and none of
such SEC Filings shall contain any untrue statement of a material fact or omit
to state any material fact required to be stated therein or necessary to make
the statements therein, in light of the circumstances under which they were made
not misleading.
 
(g)          Executed Drawdown Notice. The Investor shall have received the
Drawdown Notice executed by an officer of the Company and the representations
contained in such Drawdown Notice shall be true and correct as of each Closing.
 
 Section 6.            Brokers and Finders.
 
The Company shall not be obligated to pay any commission, brokerage fee or
finder’s fee based on any alleged agreement or understanding between Purchaser
and a third person in respect of the transactions contemplated
hereby.  Purchaser hereby agrees to indemnify the Company against any claim by
any third person for any commission, brokerage or finder's fee or other payment
with respect to this Agreement or the transactions contemplated hereby based on
any alleged agreement or understanding between Purchaser and such third person,
whether express or implied from the actions of Purchaser.
 
Section 7.             Successors and Assigns.
 
This Agreement shall bind and inure to the benefit of the Company, Purchaser and
their respective successors and assigns.
 
Section 8.              Entire Agreement.
 
This Agreement and the other writings and agreements referred to in this
Agreement or delivered pursuant to this Agreement contain the entire
understanding of the parties with respect to the subject matter hereof and
supersedes all prior agreements and understandings among the parties with
respect thereto.
 
 
6

--------------------------------------------------------------------------------

 
 
Section 9.              Notices.
 
All notices, demands and requests of any kind to be delivered to any party in
connection with this Agreement shall be in writing and shall be deemed to have
been duly given if personally delivered or if sent by internationally-recognized
overnight courier or by registered or certified mail, return receipt requested
and postage prepaid, addressed as follows:
 
if to the Company, to:
 
BioNeutral Group, Inc.
211 Warren Street
Newark, New Jersey 07103
Attention:  President

if to Purchaser, to:
 
Vinfluence Pty Ltd ACN 147 137 899
Level 14 No 1 Alfred Street Sydney
Australia
Email: Wayne@noblemenventures.com

or to such other address as the party to whom notice is to be given may have
furnished to the other parties to this Agreement in writing in accordance with
the provisions of this Section 8.  Any such notice or communication shall be
deemed to have been received (i) in the case of personal delivery, on the date
of such delivery, (ii) in the case of internationally-recognized overnight
courier, on the next business day after the date when sent and (iii) in the case
of mailing, on the third business day following that on which the piece of mail
containing such communication is posted.
 
Section 10.           Amendments.
 
This Agreement may not be modified or amended, or any of the provisions of this
Agreement waived, except by written agreement of the Company and Purchaser.
 
Section 11.           Governing  Law; Waiver of Jury Trial.
 
All questions concerning the construction, interpretation and validity of this
Agreement shall be governed by and construed and enforced in accordance with the
domestic laws of New York without giving effect to any choice or conflict of law
provision or rule (whether in the State of New York or any other jurisdiction)
that would cause the application of the laws of any jurisdiction other than the
State of New York.  In furtherance of the foregoing, the internal laws of the
State of New York will control the interpretation and construction of this
Agreement, even if under such jurisdiction's choice of law or conflict of law
analysis, the substantive law of some other jurisdiction would ordinarily or
necessarily apply.
 
 
7

--------------------------------------------------------------------------------

 
 
BECAUSE DISPUTES ARISING IN CONNECTION WITH COMPLEX FINANCIAL TRANSACTIONS ARE
MOST QUICKLY AND ECONOMICALLY RESOLVED BY AN EXPERIENCED AND EXPERT PERSON AND
THE PARTIES WISH APPLICABLE LAWS TO APPLY (RATHER THAN ARBITRATION RULES), THE
PARTIES DESIRE THAT THEIR DISPUTES BE RESOLVED BY A JUDGE APPLYING SUCH
APPLICABLE LAWS.  THEREFORE, TO ACHIEVE THE BEST COMBINATION OF THE BENEFITS OF
THE JUDICIAL SYSTEM AND OF ARBITRATION, THE PARTIES HERETO WAIVE ALL RIGHT TO
TRIAL BY JURY IN ANY ACTION, SUIT OR PROCEEDING BROUGHT TO ENFORCE OR DEFEND ANY
RIGHTS OR REMEDIES UNDER THIS AGREEMENT OR ANY DOCUMENTS RELATED HERETO.
 
Section 12.           Assignment; Termination
 
       12.1                 Assignment.  Neither this Agreement nor any rights
of the Company hereunder may be assigned to any other Person.
 
       12.2                 Termination.  The obligations of the Purchaser to
make Advances under this Agreement shall terminate at the end of the Commitment
Period.
 
Section 13.           Submission to Jurisdiction.
 
Any legal action or proceeding with respect to this Agreement may be brought in
the courts of Australia, by execution and delivery of this Agreement, the
Company hereby accepts for itself and in respect of its property, generally and
unconditionally, the jurisdiction of the aforesaid courts.  Purchaser hereby
irrevocably waives, in connection with any such action or proceeding, any
objection, including, without limitation, any objection to the venue or based on
the grounds of forum non conveniens, which it may now or hereafter have to the
bringing of any such action or proceeding in such respective
jurisdictions.  Purchaser hereby irrevocably consents to the service of process
of any of the aforementioned courts in any such action or proceeding by the
mailing of copies thereof by registered or certified mail, postage prepaid, to
it at its address as set forth herein.
 
Section 14.           Severability.
 
It is the desire and intent of the parties that the provisions of this Agreement
be enforced to the fullest extent permissible under the law and public policies
applied in each jurisdiction in which enforcement is sought.  Accordingly, in
the event that any provision of this Agreement would be held in any jurisdiction
to be invalid, prohibited or unenforceable for any reason, such provision, as to
such jurisdiction, shall be ineffective, without invalidating the remaining
provisions of this Agreement or affecting the validity or enforceability of such
provision in any jurisdiction.  Notwithstanding the foregoing, if such provision
could be more narrowly drawn so as not to be invalid, prohibited or
unenforceable in such jurisdiction, it shall, as to such jurisdiction, be so
narrowly drawn, without invalidating the remaining provisions of this Agreement
or affecting the validity or enforceability of such provision in any other
jurisdiction.
 
Section 15.           Independence of Agreements, Covenants, Representations and
Warranties.
 
All agreements and covenants hereunder shall be given independent effect so that
if a certain action or condition constitutes a default under a certain agreement
or covenant, the fact that such action or condition is permitted by another
agreement or covenant shall not affect the occurrence of such default, unless
expressly permitted under an exception to such covenant.  In addition, all
representations and warranties hereunder shall be given independent effect so
that if a particular representation or warranty proves to be incorrect or is
breached, the fact that another representation or warranty concerning the same
or similar subject matter is correct or is not breached will not affect the
incorrectness of or a breach of a representation and warranty hereunder.  The
exhibits and any schedules attached hereto are hereby made part of this
Agreement in all respects.
 
 
8

--------------------------------------------------------------------------------

 
 
Section 16.           Counterparts.
 
This Agreement may be executed in any number of counterparts, and each such
counterpart of this Agreement shall be deemed to be an original instrument, but
all such counterparts together shall constitute but one agreement.  Facsimile
and .pdf counterpart signatures to this Agreement shall be acceptable and
binding.
 
Section 17.           Headings.
 
The section and paragraph headings contained in this Agreement are for reference
purposes only and shall not affect in any way the meaning or interpretation of
this Agreement.
 
Section 18.           Expenses.
 
Purchaser shall pay Purchaser’s own fees and expenses incurred in connection
with the negotiation, review, execution and delivery of the Financing Documents.
 
Section 19.           Preparation of Agreement.
 
Each party to this Agreement acknowledges that:  (i) the party had the advice
of, or sufficient opportunity to obtain the advice of, legal counsel separate
and independent of legal counsel for any other party hereto; (ii) the terms of
the transactions contemplated by this Agreement are fair and reasonable to such
party; and (iii) such party has voluntarily entered into the transactions
contemplated by this Agreement without duress or coercion.  Each party further
acknowledges that such party was not represented by the legal counsel of any
other party hereto in connection with the transactions contemplated by this
Agreement, nor was he or it under any belief or understanding that such legal
counsel was representing his or its interests.  Each party agrees that no
conflict, omission or ambiguity in this Agreement, or the interpretation
thereof, shall be presumed, implied or otherwise construed against any other
party to this Agreement on the basis that such party was responsible for
drafting this Agreement.

[SIGNATURE PAGE FOLLOWS]
 
 
9

--------------------------------------------------------------------------------

 
 
IN WITNESS WHEREOF, each of the undersigned has duly executed this Preferred
Stock Drawdown Agreement as of the date first written above.
 
COMPANY:

BIONEUTRAL GROUP, INC.

By:  /s/ Andrew Kielbania           
Name: Andrew Kielbania
           Title: Interim Chief Executive Officer

 

 
PURCHASER:

 
Vinfluence Pty Ltd ACN 147 137 899

 
 
/s/ Wayne Johnson                                

 
Signature of Trustee
 
Address:
 
 
Telephone:
 
Telecopier:
 
 
10

--------------------------------------------------------------------------------

 
 
EXHIBIT A
DRAWDOWN NOTICE

BioNeutral Group, Inc.
 
The undersigned, ______________ hereby certifies with respect to the sale of
shares of Preferred Stock of BioNeutral Group, Inc. (the “Company”) issuable in
connection with Drawdown Notice, delivered pursuant to the Preferred Stock
Drawdown Agreement (the “Agreement”), as follows:

1.  The undersigned is duly elected ___________ of the Company.

2.  There are no fundamental changes to the business of the Company which
constitute a fundamental change in the nature of the Company’s business.

3.  The Company has performed in all material respects all covenants and
agreements to be performed by the Company and has complied in all material
respects with all obligations and conditions contained in the Agreement on or
prior to the Drawdown Notice Date.
 
4.  The undersigned hereby represents, warrants and covenants that it has made
all filings (“SEC Filings”) required to be made by it pursuant to applicable
securities laws (including, without limitation, all filings required under the
Securities Exchange Act of 1934, which include Forms 10-Q, 10-K, 8-K,
etc.).  All SEC Filings and other public disclosures made by the Company,
including without limitation, all press releases, analysts meetings and calls,
etc. (collectively, the “Public Disclosures”), have been reviewed and approved
for release by the Company’s attorneys and, if containing financial information,
the Company’s independent certified public accountants.  None of the Company’s
Public Disclosures contain any untrue statement of a material fact of omit to
state any material fact required to be stated therein or necessary to make the
statements therein, in the light of the circumstances under which they were
made, not misleading.

5.  The Advance requested is ___________________.

The undersigned has executed this Certificate this ________ day of _________.

BioNeutral Group, Inc.

By: ________________________
       Name:
       Title:
 
 
11

--------------------------------------------------------------------------------

 
 
EXHIBIT B

Certificate of Designation
For Nevada Corporations
(Pursuant to NRS 78.1955)
BIONEUTRAL GROUP, INC.
File Number: [___________]

Series E Convertible Preferred Stock, to consist of 140,000 shares of the
5,000,000 Authorized shares of Preferred Stock; and have the following terms:

1. Designation, Amount and Par Value.  The series of preferred stock shall be
designated as its Series C Convertible Preferred Stock (the “Preferred Stock”)
and the number of shares so designated shall be 140,000 (which shall not be
subject to increase without the consent of the holders of a majority of the
Preferred Stock (each, a “Holder” and collectively, the “Holders”)).  Each share
of Preferred Stock shall have a par value of $.001 per share and a stated value
equal to the sum of $10 plus all accrued and unpaid dividends to the date of
determination to the extent not previously paid in cash or common stock, par
value $.00001 per share (“Common Stock”) of the Company in accordance with the
terms hereof (the “Stated Value”).

2. Dividends. Except as provided herein, the holders of outstanding shares of
the Preferred Stock shall be entitled to receive cash, stock, or other property,
as dividends when, as, and if declared by the Board of Directors of the Company.
If shares of the Preferred Stock or the common stock of the Company, par value
$0.00001 per share (the "Common Stock") are to be issued as a dividend, any such
shares shall be issued at Market Value. "Market Value" for the Common Stock for
the purposes of this Certificate of Designation shall mean the average of the
bid and ask prices for the Common Stock for the five business days preceding the
declaration of a dividend by the Board of Directors. "Market Value" with respect
to any shares of the Preferred Stock shall be as determined by the Board of
Directors, whose decision shall be final and binding on all parties.

3. Liquidation Rights. Upon the dissolution, liquidation or winding up of the
Company, whether voluntary or involuntary, the holders of the then outstanding
shares of Preferred Stock shall be entitled to receive out of the assets of the
Company for each share of Preferred Stock the Stated Value (the "Liquidation
Rate") before any payment or distribution shall be made on the Common Stock, or
any other class of capital stock of the Company ranking junior to the Preferred
Stock.

(a) The sale, conveyance, exchange or transfer (for cash, shares of stock,
securities or other consideration) of all or substantially all the property and
assets of the Company shall be deemed a dissolution, liquidation or winding up
of the Company for purposes of this Paragraph 3, but the merger, consolidation,
or other combination of the Company into or with any other corporation, or the
merger, consolidation, or other combination of any other corporation into or
with the Company, shall not be deemed a dissolution, liquidation or winding up,
voluntary or involuntary, for purposes of this Paragraph 3. As used herein, the
"merger, consolidation, or other combination" shall include, without limitation,
a forward or reverse triangular merger, or stock exchange of the Company and any
of its subsidiaries with any other corporation where the Company is not the
surviving entity.
 
 
12

--------------------------------------------------------------------------------

 
 
(b) After the payment to the holders of shares of the Preferred Stock of the
full preferential amounts fixed by this Paragraph 3 for shares of the Preferred
Stock, the holders of the Preferred Stock as such shall have no right or claim
to any of the remaining assets of the Company.

(c) In the event the assets of the Company available for distribution to the
holders of the Preferred Stock upon dissolution, liquidation or winding up of
the Company shall be insufficient to pay in full all amounts to which such
holders are entitled pursuant to this Paragraph 2, no distribution shall be made
on account of any shares of a class or series of capital stock of the Company
ranking on a parity with the shares of the Preferred Stock, if any, upon such
dissolution, liquidation or winding up unless proportionate distributive amounts
shall be paid on account of the shares of the Preferred Stock, ratably, in
proportion to the full distributive amounts for which holders of all such parity
shares are respectively entitled upon such dissolution, liquidation or winding
up.

4. Conversion of Preferred Stock. At any time, the holder of shares of the
Preferred Stock shall have the right, at such holder's option, to convert any
number of shares of the Preferred Stock into shares of the Common Stock. Such
right to convert shall commence as of the date the shares of such Preferred
Stock are issued to such holder (the "Issue Date") and shall continue thereafter
for a period of five years, such period ending on the fifth anniversary of the
Issue Date. In the event that the holder of the Preferred Stock elects to
convert such shares into Common Stock, the holder shall have 10 days from the
date of such notice in which to tender his shares of Preferred Stock to the
Company.

Any such conversion shall be upon the other following terms and conditions:

(a) Conversion Rate. Subject to adjustment as provided herein, each one (1)
share of the Preferred Stock shall be convertible into fully paid and
non-assessable shares of common stock at a conversion price equal to
seventy-five percent (75%) of the average closing Bid Price of the Common Stock
over the preceding ten (10) days prior to the Drawdown Notice, subject to a
floor of $.08 per share (the “Floor Price”) (the "Conversion Rate").  Bid Price
shall mean, on any date, the closing bid price (as reported by Bloomberg L.P.)
of the Common Stock on the principal trading or market for the Common Stock or
if the Common Stock is not traded on a Principal Market, the highest reported
bid price for the Common Stock.

(b) Adjustment of Floor Price for Dilution and Other Events. In order to prevent
dilution of the rights granted to the holders of shares of the Preferred Stock,
the Floor Price will be subject to adjustment from time to time as follows:

(i) Adjustment of Floor Price upon Subdivision or Combination of the Common
Stock. If the Company at any time subdivides (by any stock split, stock
dividend, recapitalization or otherwise) the authorized Common Stock into a
greater number of shares, the Floor Price in effect immediately prior to such
subdivision will be proportionately increased. If the Company at any time
combines (by combination, reverse stock split or otherwise) the authorized
Common Stock into a smaller number of shares, the Floor Price in effect
immediately prior to such combination will be proportionately reduced.

 
13

--------------------------------------------------------------------------------

 
 
(ii) Reorganization, Reclassification, Consolidation, Merger or Sale. Any
recapitalization, reorganization, reclassification, consolidation, merger, or
other similar transaction which is effected in such a way that holders of the
Common Stock are entitled to receive (either directly or upon subsequent
liquidation) stock, securities or assets with respect to or in exchange for the
Common Stock is referred to herein as an "Organic Change." Prior to the
consummation of any Organic Change, the Company will make appropriate provision,
in form and substance satisfactory to the holders of a majority of the
outstanding shares of the Preferred Stock, to ensure that each of the holders of
shares of the Preferred Stock will thereafter have the right to acquire and
receive in lieu of or in addition to, as the case may be, the shares of the
Common Stock immediately theretofore acquirable and receivable upon the
conversion of such holder's Preferred Stock, such shares of stock, securities or
assets as may be issued or payable with respect to or in exchange for the number
of shares of the Common Stock immediately theretofore acquirable and receivable
upon the conversion of such holder's shares of the Preferred Stock had such
Organic Change not taken place. In any such case, the Company will make
appropriate provision, in form and substance satisfactory to the holders of a
majority of the outstanding shares of the Preferred Stock, with respect to such
holders' rights and interests to ensure that the provisions of this paragraph
will thereafter be applicable to the Preferred Stock The Company will not effect
any such consolidation or merger, unless prior to the consummation thereof the
successor entity resulting from such consolidation or merger, if other than the
Company, assumes, by written instrument, in form and substance satisfactory to
the holders of a majority of the outstanding shares of the Preferred Stock, the
obligation to deliver to each holder of shares of the Preferred Stock such
shares of stock, securities or assets as, in accordance with the foregoing
provisions, that such holder may be entitled to acquire.

(iii) Notices. Immediately upon any adjustment of the Floor Price, the Company
will give written notice of such adjustment to each holder of shares of the
Preferred Stock, setting forth in reasonable detail and certifying the
calculation of such adjustment. The Company will give written notice to each
holder of shares of the Preferred Stock at least 20 days prior to the date on
which the Company closes its books or takes a record with respect to any
dividend or distribution upon the Common Stock, or with respect to any pro rata
subscription offer to holders of the Common Stock. The Company will also give
written notice to each holder of shares of the Preferred Stock at least 20 days
prior to the date on which any Organic Change, dissolution or liquidation will
take place.

(c) Mechanics of Conversion. To convert shares of the Preferred Stock into
shares of the Common Stock on any date (the "Conversion Date"), the holder
thereof shall (i) deliver or transmit by facsimile to the Company, for receipt
on or prior to l1:59 p.m. Eastern Time, on the Conversion Date, a copy of a
fully executed notice of conversion in the form attached hereto as Exhibit A
(the "Conversion Notice"), and (ii) surrender to a common carrier for delivery
to the Company as soon as practicable following such date, the certificates
(each a "Preferred Stock Certificate") representing the shares of the Preferred
Stock being converted, or an indemnification undertaking with respect to such
shares in the case of the loss, theft or destruction thereof, and the originally
executed Conversion Notice. Upon receipt by the Company of a facsimile copy of a
Conversion Notice, the Company shall immediately send, via facsimile, a
confirmation of receipt of such Conversion Notice to such holder. Within three
business days of the Company's receipt of the originally executed Conversion
Notice and the holder's Preferred Stock Certificate(s), the Company shall issue
and surrender to a common carrier for overnight delivery to the address as
specified in the Conversion Notice, a certificate, registered in the name of the
holder or its designee, for the number of shares of the Common Stock to which
the holder is entitled, or at the holder’s option, delivery of the shares of
Common Stock via the DWAC system to holder’s brokerage account.
 
 
14

--------------------------------------------------------------------------------

 
 
(d)  Certain Conversion Restrictions.
 
(A) A Holder may not convert shares of Preferred Stock or receive shares of
Common Stock as payment of dividends hereunder to the extent such conversion or
receipt of such dividend payment would result in the Holder, together with any
affiliate thereof, beneficially owning (as determined in accordance with Section
13(d) of the Securities Exchange Act of 1934, as amended (“Exchange Act”) and
the rules promulgated thereunder) in excess of 4.999% of the then issued and
outstanding shares of Common Stock, including shares issuable upon conversion
of, and payment of dividends on, the shares of Preferred Stock held by such
Holder after application of this Section.  Since the Holder will not be
obligated to report to the Company the number of shares of Common Stock it may
hold at the time of a conversion hereunder, unless the conversion at issue would
result in the issuance of shares of Common Stock in excess of 4.999% of the then
outstanding shares of Common Stock without regard to any other shares which may
be beneficially owned by the Holder or an affiliate thereof, the Holder shall
have the authority and obligation to determine whether the restriction contained
in this Section will limit any particular conversion hereunder and to the extent
that the Holder determines that the limitation contained in this Section
applies, the determination of which portion of the shares of Preferred Stock are
convertible shall be the responsibility and obligation of the Holder.  The
provisions of this Section may be waived by a Holder (but only as to itself and
not to any other Holder) upon not less than 61 days prior notice to the
Company.  Other Holders shall be unaffected by any such waiver.
 
(B) A Holder may not convert shares of Preferred Stock or receive shares of
Common Stock as payment of dividends hereunder to the extent such conversion or
receipt of such dividend payment would result in the Holder, together with any
affiliate thereof, beneficially owning (as determined in accordance with Section
13(d) of the Exchange Act and the rules promulgated thereunder) in excess of
9.999% of the then issued and outstanding shares of Common Stock, including
shares issuable upon conversion of, and payment of dividends on, the shares of
Preferred Stock held by such Holder after application of this Section.  Since
the Holder will not be obligated to report to the Company the number of shares
of Common Stock it may hold at the time of a conversion hereunder, unless the
conversion at issue would result in the issuance of shares of Common Stock in
excess of 9.999% of the then outstanding shares of Common Stock without regard
to any other shares which may be beneficially owned by the Holder or an
affiliate thereof, the Holder shall have the authority and obligation to
determine whether the restriction contained in this Section will limit any
particular conversion hereunder and to the extent that the Holder determines
that the limitation contained in this Section applies, the determination of
which portion of the shares of Preferred Stock are convertible shall be the
responsibility and obligation of the Holder.  The provisions of this Section may
be waived by a Holder (but only as to itself and not to any other Holder) upon
not less than 61 days prior notice to the Company. Other Holders shall be
unaffected by any such waiver.
 
 
15

--------------------------------------------------------------------------------

 
 
(e) Record Holder. The person or persons entitled to receive shares of the
Common Stock issueable upon conversion of shares of the Preferred Stock shall be
treated for all purposes as the record holder or holders of such shares of the
Common Stock on the Conversion Date.

(f) Fractional Shares. The Company shall not be required to issue any fraction
of a share of the Common Stock upon any conversion. All shares of the Common
Stock, including fractions thereof, issue able upon conversion of more than one
share of the Preferred Stock shall be aggregated for purposes of determining
whether the conversion would result in the issuance of a fraction of a share of
the Common Stock. If, after such aggregation, the issuance would result in the
issuance of a fraction of a share of the Common Stock, the Company shall round
such fraction of a share of the Common Stock up or down to the nearest whole
share.

(g) Re-issuance of Certificates. In the event of a conversion of less than all
of the shares of the Preferred Stock represented by a particular Preferred Stock
Certificate, the Company shall promptly cause to be issued and delivered to the
holder of such Preferred Stock a new Preferred Stock Certificate representing
the remaining shares of the Preferred Stock which were not corrected.

5. Reservation of Shares. The Company shall, so long as any of the shares of the
Preferred Stock are outstanding, reserve and keep available out of its
authorized and unissued shares of the Common Stock, solely for the purpose of
effecting the conversion of the shares of the Preferred Stock, the number of
shares of the Common Stock as shall from time to time be sufficient to affect
the conversion of all of the outstanding shares of the Preferred Stock.

6. Lost or Stolen Certificates. Upon receipt by the Company of evidence
satisfactory to the Company of the loss, theft, destruction or mutilation of any
Preferred Stock Certificates representing shares of the Preferred Stock, and, in
the case of loss, theft or destruction, of any indemnification undertaking or
bond, in the Company's discretion, by the holder to the Company and, in the case
of mutilation, upon surrender and cancellation of the Preferred Stock
Certificate(s), the Company shall execute and deliver new Preferred Stock
Certificate(s) of like tenor and date.
 
7. Voting Rights.  Except as otherwise provided herein and as otherwise required
by law, the Preferred Stock shall have no voting rights.  However, so long as
any shares of Preferred Stock are outstanding, the Company shall not, without
the affirmative vote of the Holders of a majority of the shares of the Preferred
Stock then outstanding, (a) alter or change adversely the powers, preferences or
rights given to the Preferred Stock or alter or amend this Certificate of
Designation, (b) authorize or create any class of stock ranking as to dividends
or distribution of assets upon a Liquidation (as set forth in Section 3) senior
to or otherwise pari passu with the Preferred Stock, (c) amend its certificate
or articles of incorporation or other charter documents so as to affect
adversely any rights of the Holders, (d) increase the authorized number of
shares of Preferred Stock, or (e) enter into any agreement with respect to the
foregoing.

 
16

--------------------------------------------------------------------------------

 
 
NOTICE OF CONVERSION
 
(To be Executed by the Registered Holder
in order to convert shares of Preferred Stock)

The undersigned hereby elects to convert the number of shares of Series E
Convertible Preferred Stock indicated below, into shares of common stock, par
value $.00001 per share (the “Common Stock”), of BioNeutral Group, Inc., a
Nevada corporation (the “Company”), according to the conditions hereof, as of
the date written below.  If shares are to be issued in the name of a person
other than undersigned, the undersigned will pay all transfer taxes payable with
respect thereto and is delivering herewith such certificates and opinions as
reasonably requested by the Company in accordance therewith.  No fee will be
charged to the Holder for any conversion, except for such transfer taxes, if
any.  By tendering this Notice of Conversion, the undersigned hereby covenants
to comply with the prospectus delivery requirements under the Securities Act of
1933, as amended, applicable to it with respect to resales of the shares of
Common Stock issuable upon the conversion requested hereby pursuant to a
registration statement and, in connection therewith, covenants that, unless
otherwise specified below, such shares have been or are intended to be sold in
ordinary brokerage transactions.
 

 Conversion calculations:              Date to Effect Conversion                
 Number of shares of Preferred Stock owned prior to Conversion                
 Number of shares of Preferred Stock to be Converted                  Stated
Value of shares of Preferred Stock to be Converted                  Number of
shares of Common Stock to be Issued                  Applicable Conversion Price
                 Number of shares of Preferred Stock subsequent to Conversion  
               Signature                  Name                  Address  

 

Accepted and Agreed:
BioNeutral Group, Inc.

By:_____________________________________
     Name:
     Title:
 
 
 
17

--------------------------------------------------------------------------------